Learn about key study results presented during ESMO Congress 2021!
ESMO Highlight videos aim to cover results from a selection of important studies presented during the Congress.
Monday 20 September
Enriqueta Felip reports on LBA9 - IMpower010: patterns of relapse and subsequent therapy from a Phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in stage IB-IIIA non-small cell lung cancer (NSCLC)
Athanassios Argiris reports on LBA36 - CheckMate 651, a phase III trial of nivolumab/ipilimumab versus EXTREME regimen in first-line treatment of recurrent or metastatic SCCHN
Sunday 19 September
Jared Weiss reports on LBA6 - KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or in Combination With Cetuximab in Patients (Pts) With Colorectal Cancer (CRC) Harboring a KRASG12C Mutation
Susana Banerjee reports on 725MO - Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer (FRAME)
Gerhardt Attard reports on LBA4_PR - Abiraterone acetate and prednisolone (AAP) or AAP and enzalutamide (enza) added to androgen deprivation therapy (ADT) for men with high-risk locally advanced prostate cancer (PCa): metastases-free survival (MFS) results from STAMPEDE (NCT00268476)
Hope Rugo reports on LBA16 - Final results of KEYNOTE-355: A randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
Thierry Conroy reports on LBA57 - Unicancer GI PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter randomized phase 3 trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas.
Saturday 18 September
Nicoletta Colombo reports on LBA2_PR - KEYNOTE-826: A randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Jason Luke reports on LBA3_PR - Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the Keynote 716 double-blinded phase III trial
Chiara Cremolini reports on LBA20 - FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO
Friday 17 September
Nicolas Girard reports on LBA66 - Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial
Thomas Powles reports on LBA27 - Erdafitinib (ERDA) or ERDA Plus Cetrelimab (CET) for Patients With Metastatic or Locally Advanced Urothelial Carcinoma (mUC) and Fibroblast Growth Factor Receptor Alterations (FGFRa): First Phase 2 Results From the NORSE Study
Susana Banerjee reports on LBA32 - Principal results of the EORTC-1508 trial: A phase II randomised study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Eric Pujade-Lauraine reports on LBA33 - Retreatment with maintenance olaparib in patients (pts) with ovarian cancer (OC) previously treated with a PARP inhibitor (PARPi): randomized Phase IIIb OReO/ENGOT Ov-38 trial